Caris Life Sciences (CAI) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- —
- Estimate
- $0.01
- Surprise
- -100.0%
- Revenue (period 2026-06-30)
- $263.7M
- Score at report (before → after)
- 6.8 → 6.7/10
Revenue source: xbrl.
How the report landed
TrendMatrix's engine moved from Hold (6.8/10) to Buy (Wait) at 6.7/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CAI Sell at 5.6/10.
2 of the last 4 quarters beat the estimate; this quarter's -100.0% surprise compares with a +81.9% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Product: MI Profile tissue-based profiling (84.4%)
- Concentration risk — Supplier: sole suppliers for next-generation sequencers
- Cyclical trap - fwd PE 75x vs trail 16x (4.6x)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $27.45
- Price target
- $32.23
- Stop
- $25.53
- Upside to target
- +17.4%
Forward estimates sit below the trailing run-rate (75.5× forward vs 16.2× trailing) — consensus expects earnings to decline from here.
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
CAI at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $7.76B
- P/E (fwd)
- 75.5
- P/E (ttm)
- 16.2
- 52-week range
- $14.19–$33.66
- Off 52-week high
- 18.4%
- RSI (14)
- 47
- Volume vs avg
- 0.95×
- Score today
- 5.6/10